HER-2 testing in breast cancer using parallel tissue-based methods.

Yaziji, Hadi; Goldstein, Lynn C; Barry, Todd S; Werling, Robert; Hwang, Harry; Ellis, Georgiana K; Gralow, Julie R; Livingston, Robert B; Gown, Allen M

Yaziji, Hadi; Goldstein, Lynn C; Barry, Todd S; Werling, Robert; Hwang, Harry; Ellis, Georgiana K; Gralow, Julie R; Livingston, Robert B; Gown, Allen M.

Affiliation

Yaziji H; PhenoPath Laboratories, Seattle, Wash 98103, USA.

JAMA ; 291(16): 1972-7, 2004 Apr 28.

Article in En | MEDLINE | ID: mdl-15113815

Subject(s)

Breast Neoplasms/genetics; Genes, erbB-2; Immunohistochemistry; In Situ Hybridization, Fluorescence; Receptor, ErbB-2/metabolism; Adult; Aged; Aged, 80 and over; Algorithms; Antibodies, Monoclonal/therapeutic use; Antibodies, Monoclonal, Humanized; Antineoplastic Agents/therapeutic use; Breast Neoplasms/drug therapy; Breast Neoplasms/metabolism; Breast Neoplasms/pathology; Genetic Testing/methods; Genetic Testing/standards; Humans; Immunohistochemistry/standards; In Situ Hybridization, Fluorescence/standards; Middle Aged; Predictive Value of Tests; Quality Control; Sensitivity and Specificity; Trastuzumab

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Immunohistochemistry / In Situ Hybridization, Fluorescence / Receptor, ErbB-2 / Genes, erbB-2 Type of study: Diagnostic_studies / Prognostic_studies Limits: Adult / Aged / Aged80 / Humans / Middle aged Language: En Journal: JAMA Year: 2004 Type: Article Affiliation country: United States

Search on Google

XML

PubMed Links